AU764760B2 - Use of inhibitors of protein kinase C epsilon to treat pain - Google Patents
Use of inhibitors of protein kinase C epsilon to treat pain Download PDFInfo
- Publication number
- AU764760B2 AU764760B2 AU48631/99A AU4863199A AU764760B2 AU 764760 B2 AU764760 B2 AU 764760B2 AU 48631/99 A AU48631/99 A AU 48631/99A AU 4863199 A AU4863199 A AU 4863199A AU 764760 B2 AU764760 B2 AU 764760B2
- Authority
- AU
- Australia
- Prior art keywords
- pkce
- pain
- inhibitor
- hyperalgesia
- epinephrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 109
- 208000002193 Pain Diseases 0.000 title claims abstract description 100
- 230000036407 pain Effects 0.000 title claims abstract description 87
- 108010078137 Protein Kinase C-epsilon Proteins 0.000 title abstract description 7
- 102000014458 Protein Kinase C-epsilon Human genes 0.000 title abstract 6
- 208000004454 Hyperalgesia Diseases 0.000 claims abstract description 120
- 208000035154 Hyperesthesia Diseases 0.000 claims abstract description 114
- 108090000315 Protein Kinase C Proteins 0.000 claims abstract description 106
- 102000003923 Protein Kinase C Human genes 0.000 claims abstract description 105
- 108010044467 Isoenzymes Proteins 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 43
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 239000000730 antalgic agent Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 101150010978 PRKCE gene Proteins 0.000 claims description 148
- 230000000694 effects Effects 0.000 claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- 102100037339 Protein kinase C epsilon type Human genes 0.000 claims description 36
- 230000001684 chronic effect Effects 0.000 claims description 22
- 206010065390 Inflammatory pain Diseases 0.000 claims description 16
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 13
- 230000001154 acute effect Effects 0.000 claims description 11
- 229940124639 Selective inhibitor Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 9
- 230000020341 sensory perception of pain Effects 0.000 claims description 9
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 206010062746 Carditis Diseases 0.000 claims description 4
- 208000001387 Causalgia Diseases 0.000 claims description 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000009525 Myocarditis Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010029240 Neuritis Diseases 0.000 claims description 4
- 206010042496 Sunburn Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 4
- 208000021646 inflammation of heart layer Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000003589 local anesthetic agent Substances 0.000 claims description 4
- 230000002981 neuropathic effect Effects 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000016192 Demyelinating disease Diseases 0.000 claims description 3
- 206010019973 Herpes virus infection Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010000269 abscess Diseases 0.000 claims description 3
- 238000002266 amputation Methods 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 230000010534 mechanism of action Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 230000037324 pain perception Effects 0.000 abstract description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 97
- 229930182837 (R)-adrenaline Natural products 0.000 description 97
- 229960005139 epinephrine Drugs 0.000 description 97
- 238000002347 injection Methods 0.000 description 46
- 239000007924 injection Substances 0.000 description 46
- 241000700159 Rattus Species 0.000 description 44
- 230000004044 response Effects 0.000 description 38
- 210000002569 neuron Anatomy 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 34
- 230000003040 nociceptive effect Effects 0.000 description 30
- 229940090044 injection Drugs 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 229940113118 carrageenan Drugs 0.000 description 25
- 239000000679 carrageenan Substances 0.000 description 25
- 235000010418 carrageenan Nutrition 0.000 description 25
- 229920001525 carrageenan Polymers 0.000 description 25
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 25
- 210000000929 nociceptor Anatomy 0.000 description 22
- 108091008700 nociceptors Proteins 0.000 description 22
- 102100026106 Probable guanine nucleotide exchange factor MCF2L2 Human genes 0.000 description 19
- 208000028389 Nerve injury Diseases 0.000 description 16
- 230000008764 nerve damage Effects 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 15
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 229940039009 isoproterenol Drugs 0.000 description 12
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 12
- 229960004528 vincristine Drugs 0.000 description 12
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 101150001670 PRKCG gene Proteins 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 230000001473 noxious effect Effects 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000000548 hind-foot Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000003766 afferent neuron Anatomy 0.000 description 8
- 230000000917 hyperalgesic effect Effects 0.000 description 8
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 229960001999 phentolamine Drugs 0.000 description 7
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 7
- 230000002035 prolonged effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000008223 sterile water Substances 0.000 description 7
- 208000000094 Chronic Pain Diseases 0.000 description 6
- 230000036982 action potential Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 229940089602 epinephrine injection Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000000472 traumatic effect Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000042846 PKC family Human genes 0.000 description 4
- 108091082203 PKC family Proteins 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 229960003712 propranolol Drugs 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 3
- 102400000967 Bradykinin Human genes 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000674 adrenergic antagonist Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 150000000093 1,3-dioxanes Chemical class 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000006749 inflammatory damage Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000012740 non-selective inhibitor Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 229940124583 pain medication Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229940100817 propranolol injection Drugs 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
- 229950010357 tetrodotoxin Drugs 0.000 description 2
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
- 241000834287 Cookeolus japonicus Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 1
- 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 229940121954 Opioid receptor agonist Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000035780 glucosuria Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 208000020469 nerve plexus disease Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008055 nociceptive signaling Effects 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008050 pain signaling Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 201000006380 plexopathy Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229940043437 protein kinase A inhibitor Drugs 0.000 description 1
- 239000012656 protein kinase A inhibitor Substances 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 108010061269 protein kinase D Proteins 0.000 description 1
- 108010065251 protein kinase modulator Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 208000000029 referred pain Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 235000008790 seltzer Nutrition 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008136 water-miscible vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9175598P | 1998-07-06 | 1998-07-06 | |
| US60/091755 | 1998-07-06 | ||
| US10376398P | 1998-10-09 | 1998-10-09 | |
| US60/103763 | 1998-10-09 | ||
| PCT/US1999/015265 WO2000001415A2 (en) | 1998-07-06 | 1999-07-06 | Use of inhibitors of protein kinase c epsilon to treat pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4863199A AU4863199A (en) | 2000-01-24 |
| AU764760B2 true AU764760B2 (en) | 2003-08-28 |
Family
ID=26784298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU48631/99A Ceased AU764760B2 (en) | 1998-07-06 | 1999-07-06 | Use of inhibitors of protein kinase C epsilon to treat pain |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1093379B1 (https=) |
| JP (1) | JP2002519391A (https=) |
| AT (1) | ATE350032T1 (https=) |
| AU (1) | AU764760B2 (https=) |
| CA (1) | CA2336709A1 (https=) |
| DE (1) | DE69934689T2 (https=) |
| ES (1) | ES2283120T3 (https=) |
| IL (1) | IL140716A0 (https=) |
| NZ (1) | NZ508767A (https=) |
| WO (1) | WO2000001415A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790192B2 (en) | 1998-08-14 | 2010-09-07 | Accessclosure, Inc. | Apparatus and methods for sealing a vascular puncture |
| AU2003234185C1 (en) | 2002-04-22 | 2009-11-19 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase C |
| US6933275B2 (en) | 2002-05-01 | 2005-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | Protein kinase C peptides for use in withdrawal |
| WO2004084889A1 (en) * | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
| EP1631309A4 (en) * | 2003-05-16 | 2010-04-28 | Univ Leland Stanford Junior | Protein kinase c peptides for use in withdrawal |
| EP1670497A4 (en) | 2003-09-16 | 2009-07-15 | Garvan Inst Med Res | METHOD FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C EPSILON (PKC &EPSIV;) AND METHOD FOR TREATING THEREOF CONVERTING DERIVED GLUCOSE METABOLISM |
| WO2006095086A2 (fr) * | 2005-03-07 | 2006-09-14 | Laurence Faure | Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence. |
| EP1869205B1 (en) * | 2005-04-02 | 2010-07-14 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Assays for determining compounds which modulate tram phosphorylation |
| US8575307B2 (en) | 2005-06-29 | 2013-11-05 | Hadasit Medical Research Services & Development Ltd. | Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes |
| EP2177510A1 (en) | 2008-10-17 | 2010-04-21 | Universität des Saarlandes | Allosteric protein kinase modulators |
| JP2010090176A (ja) * | 2010-01-26 | 2010-04-22 | Board Of Trustees Of The Leland Stanford Junior Univ | 離脱症状における使用のためのプロテインキナーゼｃペプチド |
| US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
| WO2014081029A1 (ja) * | 2012-11-26 | 2014-05-30 | 学校法人近畿大学 | 抗がん剤による末梢神経障害の予防、治療、または軽減剤 |
| EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141957A (en) * | 1990-11-02 | 1992-08-25 | Sphinx Pharmaceuticals Corporation | 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783405A (en) * | 1994-02-01 | 1998-07-21 | Terrapin Technologies, Inc. | Rapid screening method for effectors of signal transduction |
| WO1997015575A1 (en) * | 1995-10-27 | 1997-05-01 | Procyon Pharmaceuticals, Inc. | Protein kinase c modulators. y. |
-
1999
- 1999-07-06 EP EP99932296A patent/EP1093379B1/en not_active Expired - Lifetime
- 1999-07-06 DE DE69934689T patent/DE69934689T2/de not_active Expired - Lifetime
- 1999-07-06 IL IL14071699A patent/IL140716A0/xx unknown
- 1999-07-06 AT AT99932296T patent/ATE350032T1/de not_active IP Right Cessation
- 1999-07-06 CA CA002336709A patent/CA2336709A1/en not_active Abandoned
- 1999-07-06 ES ES99932296T patent/ES2283120T3/es not_active Expired - Lifetime
- 1999-07-06 NZ NZ508767A patent/NZ508767A/en not_active IP Right Cessation
- 1999-07-06 JP JP2000557861A patent/JP2002519391A/ja active Pending
- 1999-07-06 AU AU48631/99A patent/AU764760B2/en not_active Ceased
- 1999-07-06 WO PCT/US1999/015265 patent/WO2000001415A2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141957A (en) * | 1990-11-02 | 1992-08-25 | Sphinx Pharmaceuticals Corporation | 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c |
Non-Patent Citations (2)
| Title |
|---|
| CODERRE ET AL (1994) J. OF NEUROSCIENCE V6 PP 1328-1334 * |
| SCHAAP ET AL (1990) J. OF BIOL. CHEM. V265(13) P 7301-7307 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2283120T3 (es) | 2007-10-16 |
| AU4863199A (en) | 2000-01-24 |
| EP1093379A2 (en) | 2001-04-25 |
| WO2000001415A2 (en) | 2000-01-13 |
| WO2000001415A3 (en) | 2000-04-13 |
| JP2002519391A (ja) | 2002-07-02 |
| EP1093379B1 (en) | 2007-01-03 |
| DE69934689D1 (de) | 2007-02-15 |
| ATE350032T1 (de) | 2007-01-15 |
| DE69934689T2 (de) | 2007-10-25 |
| IL140716A0 (en) | 2002-02-10 |
| CA2336709A1 (en) | 2000-01-13 |
| NZ508767A (en) | 2003-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6686334B2 (en) | Use of inhibitors of protein kinase C epsilon to treat pain | |
| AU764760B2 (en) | Use of inhibitors of protein kinase C epsilon to treat pain | |
| Fundytus et al. | Knockdown of spinal metabotropic glutamate receptor 1 (mGluR1) alleviates pain and restores opioid efficacy after nerve injury in rats | |
| EP2601964B1 (en) | Balanol compounds for use in treating pain | |
| Lyons et al. | Combination drug therapy of pioglitazone and D-cycloserine attenuates chronic orofacial neuropathic pain and anxiety by improving mitochondrial function following trigeminal nerve injury | |
| Meidahl et al. | Intranasal oxytocin attenuates reactive and ongoing, chronic pain in a model of mild traumatic brain injury | |
| Niimura et al. | Changes in phosphorylation of the NMDA receptor in the rat hippocampus induced by status epilepticus | |
| Ren et al. | Inflammation and hyperalgesia in rats neonatally treated with capsaicin: effects on two classes of nociceptive neurons in the superficial dorsal horn | |
| Kimura et al. | Glial cell line‐derived neurotrophic factor‐mediated enhancement of noradrenergic descending inhibition in the locus coeruleus exerts prolonged analgesia in neuropathic pain | |
| Cheung et al. | Inhibition of protein kinase C reduces ischemia‐induced tyrosine phosphorylation of the N‐methyl‐d‐aspartate receptor | |
| Wang et al. | Metabotropic actions of the volatile anaesthetic sevoflurane increase protein kinase Mζ synthesis and induce immediate preconditioning protection of rat hippocampal slices | |
| US8492346B2 (en) | Methods of use of epsilon inhibitor compounds for the attenuation of pain | |
| Whitaker et al. | Angiotensin (1-7) contributes to nitric oxide tonic inhibition of vasopressin release during hemorrhagic shock in acute ethanol intoxicated rodents | |
| Lambru et al. | Serotonergic agents in the management of cluster headache | |
| Juránek et al. | Evidence for the participation of glutamate in reflexes involving afferent, substance P‐containing nerve fibres in the rat | |
| Clement et al. | ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential. Cells 2022, 11, 2406 | |
| D'Souza | Modulation of Spinal Dorsal Horn Long-Term Potentiation by Non-Ionotropic NMDA Receptor Activity | |
| de Sousa | Effects of opioids on descending pain facilitation: Studies after cessation of chronic opioid treatment | |
| GEPPETTI et al. | Multiple mechanisms of kinin and tachykinin receptor regulation of airway | |
| FIRING | SUSTAINED REPETITIVE FIRING (SRF) | |
| Arulmani | Calcitonin gene-related peptide and migraine: Implications for therapy | |
| Grenier | Attenuation of morphine tolerance, reward, and spinal gliosis in neuropathic pain by ultra-low dose alpha2-adrenergic antagonists | |
| Arulmani | Calcitonin gene-related peptide and migraine | |
| Hudspith et al. | Sites of Analgesic Action | |
| Molander et al. | Neurochemical characterization of neuronal populations expressing protein kinase C gamma isoform in the spinal cord and gracile nucleus of the rat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Free format text: THE FORMER OWNER WAS: ROBERT O. MESSING, JON D. LEVINE |
|
| FGA | Letters patent sealed or granted (standard patent) |